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 ABSTRACT                                                                                                                                            
Therapeutic approaches to genetic disorders
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1Genetics Unit, Department of Pediatrics, Faculty of Medicine, Ain Shams 
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Although prevention is the ideal goal for genetic disorders, various types of 
therapeutic management are available. Such management approaches depend 
on the nature of the defect, how well it is understood at the genetic and bio-
chemical levels and the practical feasibility of correction. In some conditions 
certain management is now tailored to the specific genotype. The patient being 
treated may be the fetus, the infant, the child or the adult. Treatment methods 
used in genetic disorders may involve surgical, cognitive/behavioral, pharma-
cologic, dietary, envairomental avoidance, transfusion, plasma exchange, en-
zyme, behavioral, cell, or gene therapy. Some have been developed on the basis 
of knowledge of the defect in the gene and its product, whereas others are em-
pirical or aimed at controlling or mediating signs and symptoms without care.




Stem cell therapy, gene therapy, fetal 
therapy, PKU embryopathy, chaperons.
INTRODUCTION                                    
The vast majority of genetic defects are 
attributed to deficient or defective pro-
duction of structural proteins, of regu-
latory proteins, or of catalytic enzymes 
which are the gene products of structural 
genes. Albeit, a considerable proportion 
of genetic diseases results from defec-
tive regulation of functions of structural 
genes, which is a major task exerted by 
regulatory genes. This defective regu-
lation can happen at any point and can 
affect any stage of gene function and 
comprises a quite large spectrum of 
variable pathogenetic mechanisms. Ex-
amples of these mechanisms include dis-
turbed chromatin remodeling, deficient 
or defective synthesis and or functions 
of micro - or small- RNAs, defective 
regulation of mRNA processing, splic-
ing and turn over, defective monitoring 
of post-translation modifications due to 
e.g. defective chaperon actions, defec-
tive regulation of cell cycle dynamics 
that commonly results in development 
of tumors, defective regulation of mor-
phogenetic mediators with consequent 
diversion towards teratogenesis and de-
velopment of congeniral malformations. 
The list is too long and includes a wide 
variety of different mechanisms all of 
which result in pathogenesis and devel-
opment of a large number of genetic dis-
orders due to defective regulatory func-




In view of the aforementioned simpli-
fied scheme of gene function, the list of 
therapeutic approaches to genetic disor-
ders seems endless, at least theoretical-
ly. Currently, there are too many thera-
peutic approaches to genetic diseases 
targeting either the underlying pathoge-
netic mechanism (s) or aiming at reduc-
ing the side effects and deleterious con-
sequences of these diseases secondary 
to altered  pathophysiological states2. 
These therapeutic approaches include 
a wide variety of options including di-
etary management of inborn errors of 
metabolism through restriction of of-
fending substrate (e.g phenylketonuria, 
maple syrup urine disease) and removal 
of toxic products3, drug therapy for e.g. 
hypercholesterolemia, congenital adre-
nal hyperplasia and convulsive disor-
ders4, replacement therapy of abnormal 
or deficient proteins or enzymes (e.g. 
hemophilia and many storage disor-
ders), cell-tissue-organ transplantation 
(e.g for many disorders like tyrosinemia 
and polycystic kidney disease), surgical 
intervention for genetically-determined 
congenital malformations and late de-
veloping surgically correctable com-
plications and gene therapy approaches 
that comprise innumerable varieties of 
techniques aiming at correcting molec-
ular defects leading to genetic diseases 
at nearly all known pathogenetic targets 
of these defects (e.g. exon skipping for 
Duchenne muscular dystrophy).5
The Choice of the best therapeutic ap-
proaches to a certain genetic disorder is 
determined mostly by both the under-
lying pathophysiological mechanism 
(s) and the resulting deleterious com-
plications of the defect. For instance, 
genetic metabolic errors caused by de-
ficient and or defective production of 
enzymes necessary for metabolism of 
ingested food substrates (proteins, car-
bohydrates, lipids and other nutrients) 
are characterized in general by accumu-
lation of the ingested stuff in blood. In 
most cases, metabolic by-products of 
the accumulating substrate also attain 
high levels secondary to the metabolic 
block. Percolation of the accumulating 
substances to cells, tissues and organs 
follows with subsequent pathogenesis 
of toxic effects exerted on cells and tis-
sues not acquainted to the presence of 
these substances in such high concen-
trations, hence the development of clin-
ical manifestations and disease compli-
cations, e.g. neurotoxicity exerted by 
hyperphenylalanenemia in PKU and by 
hyperammonemia in urea cycle defects, 
cataract formation due to accumulation 
of the the sugar alcohol galactitol in ga-
lactosemia and the multi-organ toxicity 
observed in tyrosinemia type I due to 
the effects of the mitochondrial toxin 
succinylacetone which is a decarboxyl-
ation product of succinyl acetoacetate, 
a compound derived from the tyrosine 
catabolic intermediate fumarylacetoac-
etate. Fumarylacetoacetate itself induc-
es mitotic abnormalities and instability 
in the genome6. Taken together, these 
data form the basis for a unifying hy-
pothesis regarding the development of 
hepatocellular carcinoma in children 
with hereditary tyrosinemia.
In addition to the accumulation of the 
ingested stuff and its metabolic inter-
mediates and/or its final metabolites, 
deficiency of the products, produced in 
normal amounts in normal conditions, 
results with consequent deleterious 
complications determined by the miss-
ing physiological and metabolic func-
tions of these products. For instance, 
young women suffering from PKU give 
birth to very severely malformed chil-
dren, a condition known as PKU em-
bryopathy that comprises microcepha-
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ly, mental retardation, hypotrophy and 
cardiopathy, unless they strictly take 
up the specific diet, until the PHE level 
has lowered down to normal, before the 
beginning of gestation. Serotonin defi-
ciency, which is a feature of PKU, prob-
ably underlies the development of PKU 
embryopathy in view of its morphoge-
netic role in normal embryogenesis.7 
Therapeuric approaches to genetic 
disorders include:
1- Substrate restriction/Removal ap-
proch:
Therapeutic approaches to most genetic 
inborn errors of metabolism include a 
comprehensive handling of all aspects 
of the metabolic defects and include 
dietary restriction of intake or remov-
al of the offending substrate from diet 
e.g. restriction of protein intake in PKU 
and urea cycle defects and removal of 
galactose and fructose from diets of 
infants affected with galactosemia and 
fructosemia, respectively.8 
Removal, degradation or detoxification 
of the accumulating toxic metabolites 
represents an indispensable and integral 
part of particularly in management of 
acute decompensation states of meta-
bolic intoxication errors as well as in 
similar genetic diseases due to storage 
of ingested food constituents or stor-
age of metabolic intermediates or final 
metabolites. Examples of this approach 
include use of sodium benzoate or so-
dium phenylbutyrate, oral lactulose 
and hemodialysis/peritoneal dialysis 
in states of hyperammonemia9, use of 
plasmapheresis in Refsum disease, use 
of iron chelation in thalassemias and 
many other conditions.    
2- Substrate addition/Replacement 
approch:
Supplementation of deficient gene prod-
uct (s) represents the most proper thera-
peutic approaches for genetic diseases 
due to mutations resulting in deficient 
or defective production, or complete 
absence, of the gene products whether 
these are proteins, enzymes or other ef-
fector components. This approach is the 
oldest conventional approach adopted 
for this category of genetic defects and 
is still in practice. Treatment of hemo-
philia with anti-hemophilic globulin10, 
treatment of hypothyroidism with L-
Troxine, treatment of short stature due 
to growth hormone deficiency with GH 
and treatment of diabetes mellitus with 
insulin are just few examples. 
3- Supplementation of the deficient 
or defective enzyme:
It seems the logical and effective physi-
ological therapeutic approach for in-
born errors due to deficient production 
of the enzyme, its production in a de-
fective configuration or failure in tar-
geting the synthesized enzyme from the 
cytosol to its final destination, e.g. the 
lysosome or the peroxisomes, as is the 
case in lysosomal storage disorders and 
peroxisomal storage defects, respec-
tively. Though supplementation of de-
ficient proteins seems a straightforward 
approach, supplementation of enzymes 
is a little bit more complicated due to 
the intra-cellular and intra-organellar 
localization of most enzymes.
Enzyme replacement therapy (ERT) 
is a therapeutic approach in which the 
specific enzyme that is inactive or ab-
sent in affected individuals is replaced 
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with synthetic functional enzyme prep-
aration. ERT has been successful for the 
treatment of Type 1 Gaucher disease11, 
Fabry disease, Hurler disease and most 
recently, has received approval for 
Pompe disease. ERT is also effective 
in the non-neurological symptoms of 
Mucopolysaccharidosis Types I, II IV 
and VI, Pompe and Niemann-Pick B, 
but has not yet proven to be beneficial 
in storage diseases that primarily affect 
the central nervous system because the 
replacement enzymes do not efficiently 
cross the blood-brain barrier.
However, the invention of recombinant 
enzyme and protein, synthesis technol-
ogy by genetic engineering has made a 
revolutionary breakthrough in genetic 
therapies and marked achievements 
have been done in this respect and the 
list of genetic disorders amenable to 
treatment via this approach is regularly 
expanding (Table 1). Research trials 
are in active progress for synthesis of 
recombinant enzymes for other genetic 
errors due to enzyme deficiencies like 
storage diseases and many others.12 
Table 1: Examples of protein produced biosynthetically using recombinant DNA technology2.
Protein Disease
1. Insulin Diabetes mellitus
2. Growth hormone Short stature due to growth hormone deficiency 
3. Factor VIII Hemophilia A
4. Factor IX Hemophilia B
5. Erythropoietin Anemia
6. Alpha Galactosidase Fabry disease
In mild conditions, provision of enzyme 
co-factors or activators, mostly vita-
mins, in pharmacologic doses, might 
result in restoration of effective enzyme 
activity with remarkable improvement. 
This approach underlies the well estab-
lished use of thiamine in maple syrup 
urine disease, of pyridoxine and vitamin 
C in homocystinuria, of vitamin B12 in 
methylmalonic aciduria and many other 
metabolic errors13 (Table 2).
Table 2: Examples of vitamin – responsive inborn errors of metabolism2.
Disease                                            Deficient vitamin  Or coenzyme
1-Homocystinuria B6                                                                          
2- Methylmalonic Acidemia B12                                                                        
3- Propionic acidemia Biotin                                                               
The finding that post-translational 
modifications defects of many enzymes 
and proteins are attributable to deficient 
or defective functions of restorative 
chaperones, a subfamily of heat shock 
proteins, secondary to mutations 
affecting one or more of the chaperon 
genes family, have opened a wide and 
promising therapeutic prospective14. 
This approach aims at either provision 
of these chaperones or correction of the 
genes producing them as a new modality 
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for combating this pathogenetic 
mechanism and treatment of diseases 
caused by this pathophysiological 
alteration. 
Pharmacological chaperones are small 
molecules that specifically bind to and 
stabilize the functional form or three-
dimensional shape of a misfolded 
protein in the endoplasmic reticulum 
(ER) of a cell. When misfolded because 
of a genetic mutation, the protein (or 
enzyme) is unable to adopt the correct 
functional shape. This misfolded 
protein is recognized by the quality 
control system in the cell and destroyed, 
leading to decreased amounts of enzyme 
that gets transported from the cell’s ER 
to the cell’s lysosome, hence, reduced 
enzyme activity. The binding of the 
chaperone molecule helps the protein 
fold into its correct three-dimensional 
shape. This allows the protein to be 
properly trafficked from the ER and 
distributed to the lysosome in the cell, 
thereby increasing enzyme activity and 
cellular function, reducing substrate 
and stress on cells.15
4- Organ-tissue-cell replacement and 
transplantation:
Replacement (transplantation) therapy 
is a wide term that encompasses too 
many varied applications. The concept 
of replacement therapy is a logic one 
based on the known pathogenetic 
mechanisms of most genetic disorders. 
Insufficient production of a gene 
product or its production in a defective 
way can be corrected by replacing 
the deficient or the defective product 
with a normal natural or synthesized 
one. This reasoning demarcated the 
narrow-scale use of the concept in 
hormone replacement therapy for 
endocrinal disorders, the use of 
immunoglobulin preparations for 
humoral immunodeficiency states, the 
use of anti-hemophilic globulin for 
hemophilia, the use of recombinant 
human enzyme preparations for many 
enzyme-deficient conditions and similar 
allied disorders. 
Extension of the concept of replacement 
therapy to a wide-scale applications 
resulted in a revolutionary turn in medical 
practice. Thus, a whole organ might be 
replaced as in organ transplantation. In 
tissue transplantation, a part of an organ 
is replaced with a healthy one like 
cardiac valve transplantation, cornea 
transplantation and bone grafting. Cell 
infusion or replacement, like whole 
or fractionated blood transfusion 
or stem cell therapy is, in a sense, a 
transplantation technique. However, 
in stem cell transplantation the goal is 
to offer affected patients with a life-
long chance for these cells to replace 
defective cells, damaged tissues, or 
failing organs. 
Despite remarkable achievements in 
this field, chronic allograft rejection, 
the side effects of the long-term 
immunosuppressive treatment and 
organ shortage are still the major 
obstacles to achieving long-term 
survival. Precautionary measures 
needed to ensure success of replacement 
therapy stem mostly from fears of 
rejection of transplanted, infused or 
injected foreign material. However, 
advances in immunogenetics allowed 
for better prognoses by refining selection 
of compatible donors and expected 
advances in genetic manipulation 
techniques aiming at prediction or 
detection of rejection at its earliest 
stages16, nullifying foreign antigen 
processing and detection and induction 
antigen-specific tolerance would surely 
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lessen the risk of rejection and related 
complications to a minimum. 17&18 
One major complication facing 
organ transplant recipients is the 
requirement for life-long systemic 
immunosuppression to prevent 
rejection. The advent of immuno-
suppressive drugs participated 
actively in ensuring the success of 
transplantation therapy; however, 
their use implies potential major side 
effects to exposed patients which are 
associated with an increased incidence 
of malignancy and susceptibility 
to opportunistic infections. Many 
gene therapy techniques have been 
advented to reduce and obviate these 
risks. Gene therapy has the potential 
to eliminate problems associated with 
immunosuppression by allowing the 
production of immunomodulatory 
proteins in the donor grafts resulting 
in local rather than systemic 
immunosuppression. Alternatively, 
gene therapy approaches could 
eliminate the requirement for general 
immunosuppression by allowing the 
induction of donor-specific tolerance. 
Gene therapy interventions may also 
be able to prevent graft damage owing 
to nonimmune-mediated graft loss or 
injury and prevent chronic rejection.19  
Another major challenge to 
transplantation approaches is failure of 
transplanted organ, tissue, or cells to 
maintain their own survival. Enhanced 
apoptosis of transplanted organs or 
tissues is a common complication of 
transplantation therapy. Furthermore, 
some of the immunosuppressive drugs 
currently in clinical use might exert their 
activity at least in part through effects on 
apoptotic pathways. From the available 
data, it can be inferred that apoptosis 
contributes to the outcome after organ 
transplantation, being involved both in 
graft rejection and in transplantation 
tolerance20. Many genetic therapies 
were tried to lessen and obviate this risk 
with promising success, for instance, the 
use of heme oxygenase-1 gene transfer 
to prolong survival of cardiac allograft21 
and use of anti-apoptotic genes for 
prolonging survival of pancreatic islets 
transplantation.22    
5- Pharmacological therapy:
Like most other diseases, pharmaco-
logical or drug therapy of genetic dis-
eases occupies a pivotal role in current 
and expected, management of most of 
these diseases. The spectrum of this 
therapeutic approach is very wide and 
encompasses a very long list of both 
pharmaceutical chemicals and pharma-
ceutical biological preparations. Chem-
ical drugs used widely in management 
of genetic disorders include anti-epi-
leptics for genetically-determined sei-
zures, lipid lowering drugs for genetic 
hyperlipidemias, Nitisinone (NTBC) 
for treatment of Tyrosinemia type I, hy-
droxyurea and piracetam for treatment 
of sickle cell anemia, trimethyl glycine 
(Betaine) for treatment of homocystin-
uria (Fig. 1), the iron chelator deferox-
amine mesylate for treatment of thalas-
semias and similar chronic hemolytic 
conditions and too many other genetic 
disorders.
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Fig. 1: Methionine  metabolic pathway.
Similarly, pharmaceutical biological 
preparations have a major role in 
treatment, alleviation and prophylaxis of 
genetic diseases and their complications. 
Examples of these preparations include: 
Use of immunoglobulins in treatment 
of humoral immunodeficiency states, 
use of megavitamins therapy in 
management of many metabolic errors 
like B1 in maple syrup urine disease, 
B6 in homocystinuria, Folic acid for 
prevention of neural tube defects 
and use of α-tocopherol in Ataxia 
with vitamin E deficiency (AVED)23. 
Additional examples include the use 
of other synthetic vitamins, hormones, 
enzymes and proteins for treatment of 
genetic diseases due to defective or 
deficient production of these biological 
active and essential components.
6- Surgical intervention:
Surgical intervention for reatment of 
birth defects and possible developing 
defects in genetic disorders plays a very 
important role in management of these 
diseases. Without such an approach, 
the life of patients with surgically-
correctable congenital malformations 
would have been a real misery. The 
same guidelines applied for these 
procedures in non-genetic diseases 
apply also for genetic diseases. The 
list of congenital defects amenable for 
surgical correction either for radical 
cure or for alleviation of sufferings and 
prophylaxis against worse downhill 
progression is too long, examples of 
candidate conditions include congenital 
heart diseases, congenital urinary tract 
obstructions, congenital neural tube 
defects, congenital bone dysplasia 
and malformations, congenital 
defects of external genital organs and 
many congenital ocular and auditory 
malformations.
Fine surgical intervention, also, is 
practiced for many genetic defects with 
considerable success. For instance, 
treatment of genetically-determined 
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intractable seizure foci by bipolar 
electro-coagulation of functional 
cortex24, use of isolated or combined 
fine laser treatment for ocular visual 
defects and dysplastic conditions of 
the cornea, the retina and the choroids, 
implantation of smart micro chips 
for peripheral vaso-occlusive and 
myocardial diseases and the use of 
robotic surgery for more safe and 
effective surgical management of many 
malformation disorders reveal the role 
of fine or micro-surgical procedures in 
this therapeutic approach.
7- Fetal therapy:
Fetal therapy, or treatment of genetic 
diseases or malformations of the fe-
tus during intra-uterine life, represents 
a crucial approach to avoid progres-
sion of such diseases or malformations 
to a hopeless situation if left without 
intervention till birth. Surgical intra-
uterine management of some fetal con-
ditions either via open fetal surgery or 
minimally-invasive fetoscopic surgery 
have an important role in treatment of 
many fetal malformations. Intervention 
in hydrocephaly, many types of spina 
bifida, congenital diaphragmatic her-
nia, urinary tract obstruction and some 
congenital heart defect illustrates few 
applications of this approach in fetal 
therapy.
Fetal drug therapy and prophylaxis also 
has a crucial role in treatment and / or 
prevention of a large number of genetic 
fetal disorders. Examples of such ap-
plications include use of corticoste-
roids prevention of external genital 
masculinization in female fetuses with 
21-hydroxylase deficiency syndrome25, 
biochemical amelioration of methylma-
lonic acidemia and biotin-responsive 
multiple carboxylase deficiency, con-
trol of fetal cardiac arrhythmias with 
Amiodarone26 and treatment of fetal 
fetal goitrous hypothyroidism with L-
Thyroxine.27 
8- Gene therapy:
As the term implies, gene therapy aims 
at offering radical treatment of genetic 
diseases via correcting the underlying 
pathogenetic mechanisms of these dis-
eases at the gene level. Based on our 
knowledge of these mechanisms, a wide 
variety of techniques have been theo-
rized. Unfortunately, quite few of them 
are worthy of trial. With the exception 
of the success of classic viral-based 
gene therapy for malignant melanoma 
of the skin28 and the success of stem cell 
therapy for some selected genetic dis-
orders, the way to safe and successful 
gene therapy is still very long.  
Current trials of gene therapy tech-
niques comprise many different ap-
proaches. Some of them target the de-
ficient or defective gene function by 
trying to compensate for the lost func-
tion by offering normal counterparts of 
the diseased gene to affected cells or 
tissues through e.g. gene transfer mech-
anisms. Other techniques target the 
whole affected cells by offering normal 
cells with normal whole genomes, like 
the case in stem cell therapy. In between 
these two extremes of the spectrum, too 
many other techniques are being tested 
with hopeful expectations. These ap-
proaches aim at targeting underlying 
pathogenetic mechanisms at all possible 
stages, for example by manipulation of 
post-transcriptional effector molecules 
like mRNA by micro- or small- RNAs, 
manipulation of the translation machine 
in the cytosol by signal transducers 
or by manipulating post-translational 
events by chaperones. Such techniques 
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include, for instance, the use of the 
ability of hammerhead ribozyme to in-
duce site-specific cleavage of RNA to 
down-regulate the expression of mu-
tant alleles29, the use of RNA interfer-
ence technology (RNAi) for control of 
underlying defects in movement disor-
ders30, the use of nanoparticles, instead 
of viral vectors, as gene carriers to tar-
get cells for many diseases, e.g. lung 
cancer where nanoparticles are used to 
target cancer cells with dual tumor sup-
pressor genes31, the induction of mo-
lecular chemerism as a potent regulator 
of cell functions to alter cell behaviour 
e.g. induction of B-cell and T-cell tol-
erance for preventing graft rejection 
and prolonging survival of transplanted 
organs32،33 and use of pharmaceutical 
molecular chaperones to correct post-
translational modifications defects 
which underlie the pathogenesis of a 
considerable number of common and 
serious genetic diseases like Alzheim-
er’s disease, Parkinson’s disease, Hun-
tington’s disease, Creutzfeldt–Jakob 
disease, cystic fibrosis, Gaucher’s dis-
ease and many other degenerative and 
neurodegenerative disorders.15
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